Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application
NCT ID: NCT03509493
Last Updated: 2018-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
465 participants
OBSERVATIONAL
2017-06-01
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:
* Scenario 1: the follow-up of patients with high risk parameters for AF development for primary and secondary prevention, whereby detection of AF will result in therapeutic intervention
* Scenario 2: the realisation of monitoring of the heart rhythm of patients post intervention in a home environment
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition, depending on the target group, patients identified with AF can receive therapy in order to control the heart rhythm. These procedures (cardioversion and ablation) often result in follow-up consultations that can be avoided if the heart rhythm can be monitored remotely.
By using FibriCheck, a medically validated smartphone application, daily rhythm measurements can be performed using only the smartphone of the patient. This allows for the heart rhythm to be registered and monitored in a home environment and the data to be automatically sent to the physician. This enables the implementation of FibriCheck in two types of scenarios:
* Scenario 1: the follow-up of patients with high risk parameters for AF development for primary and secondary prevention, whereby detection of AF will result in therapeutic intervention
* Scenario 2: the realisation of monitoring of the heart rhythm of patients post intervention in a home environment
The follow-up of patients is still driven by the treating physician(s). The objective is to implement a correct and successful process management allowing a smooth implementation of "an application on prescription".
Short- and long-term benefits the project wants to prove:
Short-term:
\- AF can successfully be detected in a home environment using the FibriCheck application
Long-term: a successful detection of AF in a home environment can:
* Be the first step towards changing and improving the care pathway of the patient
* Induce therapeutic interventions in order to prevent strokes or other complications
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients without structural heart disease
FibriCheck
Digital health application
Patients with structural heart disease
FibriCheck
Digital health application
Patients with high risk parameters for AF development
FibriCheck
Digital health application
Patients post-cryptogenic stroke
FibriCheck
Digital health application
Patients post-cardioversion therapy
FibriCheck
Digital health application
Patients post-ablation therapy
FibriCheck
Digital health application
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FibriCheck
Digital health application
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 65 and older
* CHADSVASc score of 2 or more (including congestive heart failure, hypertension, age, diabetes, previous stroke, vascular disease and sex)
* Comorbidities such as: coronary artery disease, kidney insufficiency, sleep apnea or symptomatic complaints with negative Holter in the past
Group 2: Patients with structural heart disease
* Age 65 and older
* CHADSVASc score of 2 or more
* Left atrial volume indexed for body surface area (BSA) of 34 ml/m² or more, or left atrial diameter \> 5 cm
* And any of the following indicators:
* Diastolic dysfunction of at least grade 2 with restrictive filling (E/A 2 or more) or disturbed relaxation (E/A 0.8) and with E/e' septal 15 or more (E/e' lateral 10 or more) or tricuspid insufficiency (TI) of 2.8 m/s or more
* At least mitral insufficiency (grade 2/3 or 3/3) or mitral stenosis
* Hypertrophic (obstructive) cardiomyopathy
Group 3: Patients with high risk parameters for AF development
* Age 65 or more
* General Medical Record in the participating practice
* A 5-year risk of AF of at least 10% according to the CHARGE-AF risk score
Group 4: Patients post-cryptogenic stroke or TIA
\- Experienced a cryptogenic TIA or stroke in the past year since the start of the study
Group 5: Patients post-cardioversion therapy
* Confirmed AF patient based on 12-lead ECG
* Successful AF treatment using cardioversion (DCC or chemical) to convert the heart rhythm back to normal sinus rhythm
* Subjects are older than 18 years
Group 6: Patients post-ablation therapy
* Confirmed AF patient based on 12-lead ECG
* Successful AF treatment using ablation therapy to restore the heart rhythm back to sinus rhythm in the past 3 months
* Subjects are older than 18 years
Exclusion Criteria
* Pacemaker dependent heart rhythm
* Perniosis patient
* Intense callus formation
* Low adherence to protocol
* Tremor or Parkinson
* Signs of Alzheimer or dementia
* No self-care ability
* Known AF patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qompium NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ziekenhuis Oost Limburg
Genk, Limburg, Belgium
Jessa Ziekenhuis
Hasselt, Limburg, Belgium
AZ Maria Middelares
Ghent, Oost-Vlaanderen, Belgium
AC Huisartsengeneeskunde KU Leuven
Leuven, Vlaams-Brabant, Belgium
HAK Hooglede
Hooglede, West-Vlaanderen, Belgium
Jan Yperman Ziekenhuis
Ieper, West-Vlaanderen, Belgium
AZ Groeninge
Kortrijk, West-Vlaanderen, Belgium
AZ Delta Ziekenhuis
Roeselare, West-Vlaanderen, Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Beerten SG, Proesmans T, Vaes B. A Heart Rate Monitoring App (FibriCheck) for Atrial Fibrillation in General Practice: Pilot Usability Study. JMIR Form Res. 2021 Apr 7;5(4):e24461. doi: 10.2196/24461.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1
Identifier Type: -
Identifier Source: org_study_id